The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Nanocarrier-Based Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Nanocarrier-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.
The global Nanocarrier-Based Vaccine market size is expected to reach US$ 806.5 million by 2029, growing at a CAGR of 9.3% from 2023 to 2029. The market is mainly driven by the significant applications of Nanocarrier-Based Vaccine in various end use industries. The expanding demands from the Hospital, Clinic and Other,, are propelling Nanocarrier-Based Vaccine market. Adjuvants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Delivery Systems segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nanocarrier-Based Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nanocarrier-Based Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nanocarrier-Based Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nanocarrier-Based Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nanocarrier-Based Vaccine covered in this report include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis and Moderna, etc.
The global Nanocarrier-Based Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Global Nanocarrier-Based Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nanocarrier-Based Vaccine market, Segment by Type:
Adjuvants
Delivery Systems
Global Nanocarrier-Based Vaccine market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Nanocarrier-Based Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Nanocarrier-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.
The global Nanocarrier-Based Vaccine market size is expected to reach US$ 806.5 million by 2029, growing at a CAGR of 9.3% from 2023 to 2029. The market is mainly driven by the significant applications of Nanocarrier-Based Vaccine in various end use industries. The expanding demands from the Hospital, Clinic and Other,, are propelling Nanocarrier-Based Vaccine market. Adjuvants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Delivery Systems segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nanocarrier-Based Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nanocarrier-Based Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nanocarrier-Based Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nanocarrier-Based Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nanocarrier-Based Vaccine covered in this report include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis and Moderna, etc.
The global Nanocarrier-Based Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Global Nanocarrier-Based Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nanocarrier-Based Vaccine market, Segment by Type:
Adjuvants
Delivery Systems
Global Nanocarrier-Based Vaccine market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Nanocarrier-Based Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Nanocarrier-Based Vaccine
1.1 Nanocarrier-Based Vaccine Market Overview
1.1.1 Nanocarrier-Based Vaccine Product Scope
1.1.2 Nanocarrier-Based Vaccine Market Status and Outlook
1.2 Global Nanocarrier-Based Vaccine Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Nanocarrier-Based Vaccine Market Size by Region (2018-2029)
1.4 Global Nanocarrier-Based Vaccine Historic Market Size by Region (2018-2023)
1.5 Global Nanocarrier-Based Vaccine Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Nanocarrier-Based Vaccine Market Size (2018-2029)
1.6.1 North America Nanocarrier-Based Vaccine Market Size (2018-2029)
1.6.2 Europe Nanocarrier-Based Vaccine Market Size (2018-2029)
1.6.3 Asia-Pacific Nanocarrier-Based Vaccine Market Size (2018-2029)
1.6.4 Latin America Nanocarrier-Based Vaccine Market Size (2018-2029)
1.6.5 Middle East & Africa Nanocarrier-Based Vaccine Market Size (2018-2029)
2 Nanocarrier-Based Vaccine Market by Type
2.1 Introduction
2.1.1 Adjuvants
2.1.2 Delivery Systems
2.2 Global Nanocarrier-Based Vaccine Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Nanocarrier-Based Vaccine Historic Market Size by Type (2018-2023)
2.2.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Nanocarrier-Based Vaccine Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Nanocarrier-Based Vaccine Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Nanocarrier-Based Vaccine Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Nanocarrier-Based Vaccine Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Nanocarrier-Based Vaccine Revenue Breakdown by Type (2018-2029)
3 Nanocarrier-Based Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Nanocarrier-Based Vaccine Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Nanocarrier-Based Vaccine Historic Market Size by Application (2018-2023)
3.2.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Nanocarrier-Based Vaccine Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Nanocarrier-Based Vaccine Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Nanocarrier-Based Vaccine Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Nanocarrier-Based Vaccine Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Nanocarrier-Based Vaccine Revenue Breakdown by Application (2018-2029)
4 Nanocarrier-Based Vaccine Competition Analysis by Players
4.1 Global Nanocarrier-Based Vaccine Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
4.3 Date of Key Players Enter into Nanocarrier-Based Vaccine Market
4.4 Global Top Players Nanocarrier-Based Vaccine Headquarters and Area Served
4.5 Key Players Nanocarrier-Based Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Nanocarrier-Based Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Emergent BioSolutions
5.1.1 Emergent BioSolutions Profile
5.1.2 Emergent BioSolutions Main Business
5.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Products, Services and Solutions
5.1.4 Emergent BioSolutions Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.1.5 Emergent BioSolutions Recent Developments
5.2 Sanofi
5.2.1 Sanofi Profile
5.2.2 Sanofi Main Business
5.2.3 Sanofi Nanocarrier-Based Vaccine Products, Services and Solutions
5.2.4 Sanofi Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi Recent Developments
5.3 GlaxoSmithKline Biologicals
5.3.1 GlaxoSmithKline Biologicals Profile
5.3.2 GlaxoSmithKline Biologicals Main Business
5.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Products, Services and Solutions
5.3.4 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Recent Developments
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business
5.4.3 Merck Nanocarrier-Based Vaccine Products, Services and Solutions
5.4.4 Merck Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Nanocarrier-Based Vaccine Products, Services and Solutions
5.5.4 Pfizer Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Nanocarrier-Based Vaccine Products, Services and Solutions
5.6.4 Novartis Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Moderna
5.7.1 Moderna Profile
5.7.2 Moderna Main Business
5.7.3 Moderna Nanocarrier-Based Vaccine Products, Services and Solutions
5.7.4 Moderna Nanocarrier-Based Vaccine Revenue (US$ Million) & (2018-2023)
5.7.5 Moderna Recent Developments
6 North America
6.1 North America Nanocarrier-Based Vaccine Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Nanocarrier-Based Vaccine Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Nanocarrier-Based Vaccine Market Dynamics
11.1 Nanocarrier-Based Vaccine Industry Trends
11.2 Nanocarrier-Based Vaccine Market Drivers
11.3 Nanocarrier-Based Vaccine Market Challenges
11.4 Nanocarrier-Based Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
